Consistent with the mRNA evaluation, protein levels of Cdkn1a and Mdm2 were also detectably upregulated in the two W/+ sarcoma cell lines treated with ATO, in a dose-dependent manner (Fig. 4B). Here, CDKN1A is linked to sarcoma.